Blue Trust Inc. Cuts Stock Holdings in Solventum Corporation $SOLV

Blue Trust Inc. trimmed its stake in shares of Solventum Corporation (NYSE:SOLV) by 8.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,922 shares of the company’s stock after selling 679 shares during the period. Blue Trust Inc.’s holdings in Solventum were worth $525,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Chelsea Counsel Co. grew its stake in Solventum by 720.7% during the second quarter. Chelsea Counsel Co. now owns 10,595 shares of the company’s stock valued at $804,000 after acquiring an additional 9,304 shares in the last quarter. ST Germain D J Co. Inc. grew its stake in Solventum by 84.6% during the second quarter. ST Germain D J Co. Inc. now owns 825 shares of the company’s stock valued at $63,000 after acquiring an additional 378 shares in the last quarter. CX Institutional grew its stake in Solventum by 11.7% during the second quarter. CX Institutional now owns 2,376 shares of the company’s stock valued at $180,000 after acquiring an additional 249 shares in the last quarter. ORG Wealth Partners LLC purchased a new position in Solventum during the second quarter valued at $71,000. Finally, Public Employees Retirement System of Ohio grew its stake in Solventum by 0.9% during the second quarter. Public Employees Retirement System of Ohio now owns 63,719 shares of the company’s stock valued at $4,832,000 after acquiring an additional 583 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Argus raised shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 target price for the company in a research note on Tuesday, July 1st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Solventum in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of Solventum from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 9th. Morgan Stanley upgraded shares of Solventum from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Finally, Zacks Research upgraded shares of Solventum from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 15th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $84.89.

Solventum Price Performance

Solventum stock opened at $70.53 on Monday. The firm has a 50-day moving average price of $72.75 and a 200-day moving average price of $72.08. The firm has a market capitalization of $12.23 billion, a PE ratio of 32.65, a price-to-earnings-growth ratio of 2.87 and a beta of 0.50. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $85.92.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.24. The firm had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business’s revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the business earned $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, equities research analysts forecast that Solventum Corporation will post 6.58 EPS for the current year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.